|
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
1 |
[GO] |
2023―Nov―30 |
Infliximab Concentrations in Participants with Moderate to Severe COVID-19 |
Stephen J. Balevic, Dima Dandachi, Danielle Dixon, Richard M.W. Hoetelmans, Sam Bozzette, Matthew W. McCarthy |
2 |
[GO] |
2023―Sep―26 |
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19 |
Ravi Shankar P. Singh, Robert R. LaBadie, Sima S. Toussi, Haihong Shi, Jolene Kay Berg, Joel M. Neutel, Sudeepta Aggarwal |
3 |
[GO] |
2023―Mai―01 |
Ibuprofen in the Management of Viral Infections: The Lesson of COVID-19 for Its Use in Clinical Setting |
Gianmarco Marcianò, Lucia Muraca, Vincenzo Rania, Luca Gallelli |
4 |
[GO] |
2023―Apr―12 |
Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical study |
Ryosuke Shimizu, Takanobu Matsuzaki, Ryoko Oka, Takuhiro Sonoyama, Takahiro Fukuhara, Aya Kuwata, et al. (+2) Yumiko Matsuo, Ryuji Kubota |
5 |
[GO] |
2022―Dez―15 |
Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID-19: Challenges in Pharmacoepidemiologic Research |
Renato Ferreira da Silva, Ana Marta Silva, Manuela Morato, Inês Ribeiro-Vaz, Jorge Junqueira Polónia |
6 |
[GO] |
2022―Nov―18 |
Ivermectin role in the prevention of COVID-19: A systematic review and meta-analysis |
Gong-Yi Hu, Chun-An Liang, Pei-Chin Lin, Chih-Yang Lin |
7 |
[GO] |
2022―Sep―26 |
A potential drug interaction between Favipiravir and Warfarin in patients with COVID-19: A real-world observational study |
Konkanok Wattana, Suriyon Uitrakul, Nattapol Leesakulpisut, Pirawan Khunkit |
8 |
[GO] |
2022―Sep―23 |
Considerations and Challenges in the Remdesivir Covid-19 Pediatric Development Program |
Kirk Chan-Tack, Mario Sampson, Justin Earp, Vikram Arya, Lynne Yao, John Alexander, et al. (+4) Ethan Hausman, Yodit Belew, Debra Birnkrant, Kimberly Struble |
9 |
[GO] |
2022―Jun―03 |
Population Pharmacokinetics of Hydroxychloroquine Sulphate in Healthcare Workers Given for Prophylaxis Against Corona Virus Disease 2019 (COVID-19) in India |
Jeffrey Pradeep Raj, Nithya Jaideep Gogtay, Avaneesh Pandey, Ashish Kumar Kakkar, Nusrat Shafiq Khan, Mekala Padmaja, et al. (+4) Usharani Pingali, Arun Prasath Raju, Surulivelrajan Mallayasamy, Nilima Arun Kshirsagar |
10 |
[GO] |
2022―Mai―06 |
New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments |
Sajad Khiali, Taher Entezari-Maleki |
11 |
[GO] |
2022―Apr―23 |
Physiologically-Based Pharmacokinetic Modeling Approaches for Patients with SARS-CoV-2 Infection: A Case Study with Imatinib |
Jeffry Adiwidjaja, Josephine A Adattini, Alan V Boddy, Andrew J. McLachlan |
12 |
[GO] |
2022―Feb―11 |
Hypertensive Crisis following COVID-19 Vaccination |
Elnaz Khani, Taher Entezari-Maleki |
13 |
[GO] |
2021―Dez―18 |
Association between baseline use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers and death among patients tested for COVID-19 |
Sarah A. Thomas, Michael Puskarich, Michael S. Pulia, Andrew C. Meltzer, Carlos A. Camargo, D. Mark Courtney, et al. (+3) Kristen E. Nordenholz, Jeffrey A. Kline, Christopher Kabrhel |
14 |
[GO] |
2021―Nov―21 |
Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance |
Elettra Fallani, Fabio Cevenini, Pietro Enea Lazzerini, Annalisa Verdini, Simona Saponara |
15 |
[GO] |
2021―Nov―18 |
Clearance of lormetazepam, midazolam, and their conjugated metabolites by continuous venovenous hemofiltration during prolonged sedation in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
Kimberly N. Shudofsky, Paddy K. C. Janssen, N. Foudraine, Jos L. M. L. Noble |
16 |
[GO] |
2021―Aug―05 |
The Risk of SARS-COV-2 Infection and Covid-19 Severity Associated with The Exposure to Non-Steroidal Anti-Inflammatory Drugs: Systematic Review and Meta-Analysis |
Luísa Prada, Catarina D. Santos, Rita A. Baião, João Costa, Joaquim J. Ferreira, Daniel Caldeira |
17 |
[GO] |
2021―Jul―01 |
Corticosteroids in COVID-19: We should be mindful of its acute toxicities |
Mitesh Karn, Sapana Yonghang, Sadikshya Ghimire |
18 |
[GO] |
2021―Jun―22 |
Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy |
Sajad Khiali, Taher Entezari-Maleki |
19 |
[GO] |
2021―Apr―28 |
Pharmacological Predictors of Morbidity and Mortality in COVID-19 |
Christopher Oddy, James McCaul, Polly Keeling, Jonathan Allington, Dhanuja Senn, Neesha Soni, et al. (+4) Hannah Morrison, Ruwani Mawella, Thomas Samuel, John Dixon |
20 |
[GO] |
2021―Apr―19 |
Baricitinib: From Rheumatoid Arthritis to COVID-19
5 |
Sara Assadiasl, Yousef Fatahi, Banafsheh Mosharmovahed, Bahareh Mohebbi, Mohammad Hossein Nicknam |
21 |
[GO] |
2021―Apr―07 |
Clinical Equipoise in COVID-19 Vaccine Candidates Trials |
Rafael Dal-Ré |
22 |
[GO] |
2021―Feb―26 |
The Interplay between the Immune System, the Renin Angiotensin Aldosterone System (RAAS) and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review |
Hiba Naveed, Abdallah Elshafeey, Dana Al-Ali, Emmad Janjua, Areej Nauman, Hussam Kawas, et al. (+4) Ridhima Kaul, Arwa Saed Aldien, Mohamed B. Elshazly, Dalia Zakaria |
23 |
[GO] |
2021―Jan―29 |
Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review |
Elnaz Khani, Sajad Khiali, Taher Entezari-Maleki |
24 |
[GO] |
2021―Jan―21 |
AAMC Discusses Monoclonal Antibody Therapeutics for SARS-CoV-2 Infection |
Vera S. Donnenberg |
25 |
[GO] |
2020―Dez―18 |
Amantadine for COVID-19 |
Paweł Grieb, Maciej Świątkiewicz, Katarzyna Prus, Konrad Rejdak |
26 |
[GO] |
2020―Dez―04 |
Science and Evidence-based Review and Approval of COVID-19 Vaccines: A Statement of Support for the U.S. FDA |
Sudhakar M. Pai, Ahmed A. Othman, Lorraine Rusch, Joanna C. Masters, Douglas Greene, Mark Rogge, et al. (+8) Jean-Michel Gries, William Clementi, Parag Kumar, Islam Younis, Ahmed Hamed Salem, Bruce Gaynes, Gina Pastino, Hartmut Derendorf |
27 |
[GO] |
2020―Nov―21 |
Antiretrovirals for prophylaxis against COVID-19; a comprehensive literature review |
Golbarg Alavian, Kasra Kolahdouzan, Masoud Mortezazadeh, Zahra Sadat Torabi |
28 |
[GO] |
2020―Nov―12 |
Treatment with Tocilizumab for Patients with Covid-19 Infections: A Case-series Study |
Yoonsun Mo, Obed Adarkwah, John Zeibeq, Evgeny Pinelis, Jose Orsini, James Gasperino |
29 |
[GO] |
2020―Sep―04 |
Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study |
John Ferguson, Stacy Volk, Thomas Vondracek, John Flanigan, Andrew Chernaik |
30 |
[GO] |
2020―Aug―11 |
Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations |
Ping Ji, Jianmeng Chen, Amit Golding, Nikolay P. Nikolov, Bhawana Saluja, Yunzhao R. Ren, Chandrahas Sahajwalla |
31 |
[GO] |
2020―Jul―01 |
Overmedication in COVID-19 context: a report from Peru |
Raisa N. Martinez-Rivera, Alvaro Taype-Rondan |
32 |
[GO] |
2020―Jun―24 |
Clinical pharmacology considerations for developing small molecule treatments for COVID-19 |
Priya Brunsdon, Bhawana Saluja, Chandrahas Sahajwalla |
33 |
[GO] |
2020―Jun―19 |
A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome |
Sajad Khiali, Elnaz Khani, Taher Entezari-Maleki |
34 |
[GO] |
2020―Jun―14 |
Critical Need for Implementation of Clinical Pharmacology Principles in Developing Drugs for the Treatment or Prevention of COVID-19 |
Gina Pastino |
35 |
[GO] |
2020―Jun―12 |
Why your Patients’ Believing Hydroxychloroquine and Chloroquine are 90% Effective for COVID-19 is 100% Dangerous |
C. Michael White, Adrian V. Hernandez |
36 |
[GO] |
2020―Jun―08 |
Colchicine and COVID-19 |
Pablo Corral, Gonzalo Corral, Rafael Diaz |
37 |
[GO] |
2020―Mai―29 |
A Comprehensive Updated Review on SARS-CoV-2 and COVID-19 |
Yunzhao R. Ren, Amit Golding, Alfred Sorbello, Ping Ji, Jianmeng Chen, Saluja Bhawana, et al. (+6) Kimberly Witzmann, Vikram Arya, Kellie S. Reynolds, Su-Young Choi, Nikolay Nikolov, Chandrahas Sahajwalla |
38 |
[GO] |
2020―Mai―29 |
Evaluation of potential therapeutic options for COVID-19 |
Daren Austin, Malek Okour |
39 |
[GO] |
2020―Mai―23 |
Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19? |
Somayyeh Nasiripour, Farhad Zamani, Maryam Farasatinasab |
40 |
[GO] |
2020―Mai―22 |
Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin |
Luca Gallelli, Leiming Zhang, Tian Wang, Fenghua Fu |
41 |
[GO] |
2020―Mai―21 |
Intuitive Global Insight Into COVID-19 Clinical Research Activities-The “COVID-19 Map of Hope” |
Markus Ries, Konstantin Mechler, Donna L. Smith, Benjamin Herfort, Johannes Visintini, Amon Veiga Santana, et al. (+2) Alexander Zipf, Sven Lautenbach |
42 |
[GO] |
2020―Mai―21 |
TMPRSS2: Potential Biomarker for COVID-19 Outcomes |
Jonathan D. Strope, Cindy H. Chau, PharmD, William D. Figg |
43 |
[GO] |
2020―Mai―20 |
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes? |
Bruno Mégarbane, Jean-Michel Scherrmann |